A chaetoglobosin compound and its preparation method and application

Through purification of the fermentation product of the cystosin chaetoglobosin compound with significant anti-tumor and antibacterial activity, it solved the shortcomings of the development of this compound in the prior art and achieved effective use of various cancers and Vitiligo algae Inhibition demonstrates its potential in drug development.

CN116283727BActive Publication Date: 2024-11-12INST OF OCEANOLOGY - CHINESE ACAD OF SCI
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202310234239.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-13
Publication Date
2024-11-12
Estimated Expiration
2043-03-13

AI Technical Summary

Technical Problem

The prior art is difficult to effectively use chaetoglobosin compounds from fermentation products of C. fermented cyperidus, and their biological activities have not been fully developed, especially in anti-tumor and antibacterial applications.

Method used

By fermenting activated cystoglobosin compounds in solid culture medium, purifying and purifying the steps of ethyl acetate repeated extraction, reduced pressure silica gel column chromatography, gradient elution and reverse phase column chromatography, the chaetoglobosin compounds were verified and verified Its significant activity in antitumor and antibacterial aspects.

Benefits of technology

Chaetoglobosin compounds with significant anti-tumor activity were successfully prepared, which inhibited human brain tumors, esophageal cancer, colon cancer, renal cancer and bladder cancer cells. The IC50 value is less than 10μM and has a strong inhibitory activity on Vibrio algae. The MIC is 0.5 μg/mL, demonstrating its potential in drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116283727B_ABST
    Figure CN116283727B_ABST
Patent Text Reader

Abstract

The present invention relates to microbial fermentation products and their application technology in the field of drug research, specifically to a preparation method and application of chaetoglobosin compounds produced by microbial fermentation. The chemical structure of the chaetoglobosin compound is shown in Formula I, and it is prepared by fermentation and culture of Chaetomium globosum. In vitro antitumor activity tests show that the compound has significant antitumor activity. In addition, antibacterial activity tests find that the compound has strong inhibitory activity against Vibrio alginolyticus, and is expected to become a drug for treating cancer or Vibrio alginolyticus infection. The chaetoglobosin compound prepared by the present invention is produced by fermentation and culture of microorganisms, and has the characteristics of simple operation, short production cycle, low cost, etc. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of microbial medicine, and in particular to a chaetoglobosin compound obtained from a fermentation product of Chaetomium globosum, and a preparation method and application thereof. Background Art

[0002] Marine microorganisms have formed unique metabolic pathways and physiological functions due to long-term extreme living environments, and can metabolize to produce secondary metabolites with novel structures and significant activities. Chaetoglobosin compounds are a class of cytochalasin compounds with a wide range of biological activities, such as anti-tumor, antibacterial, anti-parasitic, anti-inflammatory, and antiviral activities, and have broad application prospects.

[0003] Chaetomium globosum is a saprophytic ascomycete widely distributed in terrestrial and marine environments. Its morphological characteristics and biological effects are well known in the art. The fungus can be isolated from a variety of sources. For example, there are reports that the fungus was isolated from Ulva pertusa in the coastal area (Cui CM et al, Journal of Natural Products, 2010, 73(4), 729–733), and there are also reports that the fungus was isolated from Herba Lycopodii (Huan Lijun et al, Chinese Herbal Medicine, 2020, 51(3), 576–580); however, Chaetomium globosum is often used as a biocontrol fungus to play an important role in preventing and controlling plant diseases. Summary of the invention

[0004] The object of the present invention is to provide a chaetoglobosin compound obtained from a fermentation product of Chaetomium globosum and a preparation method and application thereof.

[0005] To achieve the above object, the technical solution adopted by the present invention is:

[0006] A chaetoglobosin compound, the molecular structure of which is shown in Formula I:

[0007]

[0008] A method for preparing a chaetoglobosin compound.

[0009] 1) fermenting the activated mycelium of Chaetomium globosum in a solid culture medium, repeatedly extracting the fermentation product with ethyl acetate, combining the extracts and concentrating them to obtain a crude fermentation extract;

[0010] The Chaetomium globosum has been reported in many documents. A person skilled in the art can conveniently isolate the fungus from the offshore Ulva pertusa according to the method publicly reported in the literature (Cui CM et al, Journal of Natural Products, 2010, 73(4), 729-733), or isolate the fungus from plants such as Herba Lycopodii (Huan Lijun et al, Chinese Herbal Medicine, 2020, 51(3), 576-580); it can also be obtained through circulation in multiple collection centers, such as China Center for Type Culture Collection (CCTCC, collection number CCTCC AF 2015035), American Type Culture Collection (ATCC, collection numbers ATCC 16790 and ATCC 58917), Deutsche Sammlung von Mikroorganismen und Zellkulturen, DSMZ, deposit numbers DSM 1962 and DSM 2142), etc. In addition, the registration information of the strain ITS in the gene bank can also be easily obtained, such as NCBI (OP848144.1), NCBI (OP810867.1), etc.

[0011] 2) The crude fermentation extract in step 1) is subjected to reduced pressure silica gel column chromatography, and eluted with a gradient of petroleum ether-ethyl acetate from 20:1 to 1:1 (v / v) and a gradient of dichloromethane-methanol from 20:1 to 1:1 (v / v).

[0012] 3) purifying the fraction eluted with a gradient of petroleum ether-ethyl acetate 1:1 (v / v) in step 2) by reverse phase column chromatography using methanol-water (10:90 to 100:0, v / v) as the eluent;

[0013] 4) Collect the components eluted with methanol-water 70:30 (v / v) in step 3), separate them by gel column chromatography, and then separate and purify them by semi-preparative liquid phase (78% CH3CN / H2O, 2.5 mL / min) to obtain the compound of formula I.

[0014] Specifically:

[0015] 1) The Chaetomium globosum is cultured on a PDA (potato sucrose agar) medium at 28° C. for 7 days, the mycelium is inoculated into a solid culture medium, and the culture medium is fermented at room temperature for 39 days. The fermentation product is extracted with petroleum ether to remove small polar metabolites, and then the product is fully soaked and repeatedly extracted with ethyl acetate for 4 times, and the extracts are combined and concentrated to obtain a crude extract.

[0016] 2) The crude extract was subjected to reduced pressure silica gel column chromatography, and gradient elution was performed using a petroleum ether-ethyl acetate elution system with a gradient of 20:1 to 1:1 (v / v, the same below) and a dichloromethane-methanol elution system with a gradient of 20:1 to 1:1.

[0017] 3) collecting and concentrating the fractions eluted by the petroleum ether-ethyl acetate 1:1 in the above step 2), and gradient eluting the fractions by reverse phase silica gel column chromatography using a methanol-water elution system with a gradient of 10:90 to 100:0;

[0018] 4) collecting the methanol-water 70:30 fraction in the above step 3), and then separating it by Sephadex LH-20 methanol gel column chromatography, and then purifying it by semi-preparative liquid phase separation to obtain the chaetoglobosin compound represented by formula I.

[0019] An application of a chaetoglobosin compound, wherein the chaetoglobosin compound in formula I is used in the preparation of drugs for human brain tumors, esophageal cancer, colon cancer, kidney cancer and bladder cancer, and related lead compounds.

[0020] An application of a chaetoglobosin compound, and an application of the chaetoglobosin compound in formula I in the preparation of a drug for inhibiting Vibrio alginolyticus infection.

[0021] The advantages of the present invention are:

[0022] 1. The chaetoglobosin compounds prepared by the present invention are derived from the fermentation products of Chaetomium globosum. The compounds are prepared by a microbial fermentation method and are highly efficient and environmentally friendly.

[0023] 2. The in vitro anti-tumor activity test showed that the compound has significant anti-SF126 human brain tumor cells, TE-1 human esophageal cancer cells, HCT116 human colon cancer cells, 786-O human renal clear cell adenocarcinoma cells, and 5637 human bladder cancer cells. The half inhibitory concentration (IC 50) were 7.17, 7.54, 7.19, 7.02 and 4.52 μM, respectively. In addition, the antibacterial activity test found that the compound had a strong inhibitory activity against Vibrio alginolyticus, and its minimum inhibitory concentration (MIC) was 0.5 μg / mL. This compound is a new compound that has not been reported yet, and its mechanism of action can be further explored. It can be used to develop drugs or their lead compounds for the treatment of the above-mentioned cancers and diseases caused by Vibrio alginolyticus infection. DETAILED DESCRIPTION

[0024] The present invention is further described below in conjunction with some non-limiting specific implementation examples.

[0025] Example 1. Molecular structure of the compound

[0026] The structure of the chaetoglobosin compound isolated from the fermentation product of Chaetomium globosum is shown in formula (I) (the Arabic numerals in the formula represent the carbon atom position in the chemical structure):

[0027]

[0028] Example 2. Preparation of the compound of formula I

[0029] 1) Fermentation culture

[0030] An appropriate amount of Chaetomium globosum is inoculated on a PDA plate. Mycelium appears white on the PDA (potato sucrose agar) medium and produces white spores in the later stage. The culture is carried out at 28° C. for 7 days before use.

[0031] The mycelium of the above PDA plate was inoculated into a sterile solid culture medium and cultured at room temperature for 39 days. The fermentation product was extracted with petroleum ether to remove small polar metabolites, and then extracted with ethyl acetate for 4 times. The crude fermentation extract was obtained after merging and concentration.

[0032] The solid culture medium has a formula of 70 grams of rice, 0.1 grams of corn steep liquor, 0.3 grams of peptone and 0.05 grams of methionine per 100 milliliters of seawater.

[0033] 2) Isolation and purification of crude extract

[0034] The crude extract was segmented by vacuum silica gel (100-200 mesh) column chromatography, and gradient elution was performed in sequence using petroleum ether-ethyl acetate in a gradient of 20:1 to 1:1 (20:1, 10:1, 5:1, 2:1, 1:1, v / v, the same below) and dichloromethane-methanol in a gradient of 20:1 to 1:1 (20:1, 10:1, 5:1, 1:1) as elution solvents; and the components eluted with petroleum ether-ethyl acetate 1:1 were collected.

[0035] The collected fractions were subjected to reverse phase silica gel column chromatography and gradient eluted with methanol-water in a ratio of 10:90 to 100:0.

[0036] The methanol-water 70:30 component in the above step was collected, and then separated by Sephadex LH-20 methanol gel column chromatography, and then purified by semi-preparative liquid phase separation, using 78% acetonitrile-water as the mobile phase, the flow rate was 2.5 mL / min, and the absorption peak with a retention time of 28 min at a wavelength of 254 nm was collected to obtain a chaetoglobosin compound shown in Formula I;

[0037] Compound 1 has the following physicochemical and spectral properties:

[0038] Compound 1: Pale yellow amorphous solid, chemical formula C 31 H 34 N2O3, specific rotation [α] 25D–75 (c 0.04, MeOH); UV (MeOH) λ max (logε)221(2.76),283(1.94)nm; ECD(1.24mM,MeOH)λ max (Δε)201(–3.12),236(+0.40),268(–0.54); HR-ESI-MS m / z483.2647[M+H] + (calcd for C 31 H 35 N2O3,483.2642). 13 C-NMR and 1 H-NMR is shown in Table 1.

[0039] Table 1. Compound 1 13 C-NMR (125 MHz) and 1 H-NMR (500MHz) data (test solvent: CDCl3)

[0040]

[0041]

[0042] Example 3. Antitumor activity experiment

[0043] The following five test cell lines were selected: human brain tumor cells (SF126), human esophageal cancer cells (TE-1), human colon cancer cells (HCT116), human renal clear cell adenocarcinoma cells (786-O) and human bladder cancer cells (5637) for anti-tumor activity testing; the cell lines used were obtained through regular channels.

[0044] 1) Test cell lines and their culture

[0045] The test cell lines used in the present invention are human brain tumor cells (SF126), human esophageal cancer cells (TE-1), human colon cancer cells (HCT116), human renal clear cell adenocarcinoma cells (786-O) and human bladder cancer cells (5637), and the cells are cultured in a culture medium containing 10% fetal bovine serum. All experiments use the same batch of cell lines between the 2nd and 10th generations.

[0046] 2) Preparation of samples to be tested

[0047] The test sample is the pure compound of formula I obtained in the above example. Accurately weigh an appropriate amount of sample, add cell-grade dimethyl sulfoxide (DMSO) to dissolve and mix, and the mother solution concentration is 10mM. The cell culture medium is diluted to 10 times the concentration to be tested for activity testing. The preparation method of positive control cisplatin is the same as above.

[0048] 3) Cytotoxicity (CCK-8 method) detection:

[0049] The present invention adopts CCK-8 method to test the growth inhibition activity of tumor cells to evaluate the effect of the compound.

[0050] The principle of this test method is as follows: CCK-8 reagent contains 2-(2-methoxy-4-nitrobenzene)-3-(4-nitrobenzene)-5-(2,4-disulfonylbenzene)-2H-tetrazolium monosodium salt (WST-8), which is reduced to a highly water-soluble yellow formazan product (Formazan) by dehydrogenase in the cell mitochondria under the action of the electron carrier 1-methoxy-5-methylphenazine dimethyl sulfate (1-Methoxy PMS). The amount of formazan generated is proportional to the number of living cells. Dimethyl sulfoxide (DMSO) can dissolve these formazans deposited in cells and has a maximum absorption peak at 450 nanometers. Therefore, using an ELISA reader to detect its absorbance at a wavelength of 450 nanometers can indirectly reflect the number of living cells, thereby evaluating the effect of drugs on cell proliferation.

[0051] Testing process:

[0052] Inoculation of cells: Prepare cells into a single cell suspension using culture medium containing 10% fetal bovine serum, and inoculate 90 μL of 5×10 cells per well of a 96-well plate. 4 / mL of adherent cells and 9×10 4 / mL of suspension cells were pre-cultured at 5% CO2 and 37°C for 24h.

[0053] Add the sample solution to be tested: add 10 μL of sample solution to each well. Set one concentration for each sample in the initial screening of activity, and set up 3 replicate wells; IC 50 Eight concentrations (including 0 concentration) were measured, and three replicate wells were set for each concentration; the cells were placed in an incubator and cultured for 48 hours. The experiment set up a blank group (Blank), a control group (Control), and a drug group (Drug).

[0054] Color development: Aspirate the old culture medium and drug solution from adherent cells (add 10 μL CCK-8 stock solution directly to suspended cells), add 100 μL CCK-8 solution diluted ten times to each well, and continue culturing at 37°C, 5% CO2 for 1-4 h (keep away from light and observe in real time).

[0055] Detection: Measure the absorbance at 450nm with an enzyme-labeled instrument and record the original data results.

[0056] Calculation of proliferation inhibition rate (IR%): The OD value of three wells was averaged, and the original data was standardized using Excel software. The cell proliferation inhibition rate was calculated by the OD value of each well in the initial screening (formula = (OD Control -OD Drug ) / (OD Control -OD Blank )×100%), and the inhibition rate was calculated. IC 50 The data were calculated using GraphPad Prism 8 (version 8.0.2, GraphPad Software Inc), and the experimental results were expressed as ± SD.

[0057] IC 50 Value: The concentration of the sample solution corresponding to an inhibition rate (IR%) of 50%.

[0058] The experimental results are shown in Table 2.

[0059] Table 2. Antitumor activity (IC 50 ,μM)

[0060]

[0061] The experimental results showed that the compound had strong inhibitory activity against human brain tumor cells (SF126), human esophageal cancer cells (TE-1), human colon cancer cells (HCT116), human renal clear cell adenocarcinoma cells (786-O) and human bladder cancer cells (5637). 50 The values ​​were all less than 10 μM, and the inhibitory effect on human brain tumor cells (SF126) was better than the activity of the positive control cisplatin.

[0062] Example 4. Antibacterial activity

[0063] The minimum inhibitory concentration (MIC) method was used to detect the activity of the compound represented by Formula I against Vibrio alginolyticus.

[0064] The experimental process is as follows: using sterile operation, add sample solutions of different concentrations after multiple dilution to a sterile 96-well polystyrene plate, add sample solutions to wells 1 to 8, 5 μL per well, and select another column without adding samples as a growth control.

[0065] After the indicator bacteria suspension equivalent to 0.5 McFarland turbidity was diluted 1000 times with LB liquid medium (10g peptone, 5g yeast extract, 10g sodium chloride, 1000ml distilled water), 95μL was added to the 96-well plate in sequence, so that the final concentrations of the samples in wells 1 to 8 were 64, 32, 16, 8, 4, 2, 1, and 0.5μg / mL, respectively. After gently shaking and mixing, the 96-well plate was sealed and placed in a 37°C incubator for 24 hours.

[0066] The absorbance of each well was measured using an ELISA reader at a wavelength of 600 nm, and the lowest drug concentration that completely inhibited the growth of indicator bacteria in the well was defined as MIC. The test was meaningful only when the indicator bacteria in the negative control well grew significantly.

[0067] The experimental results showed that the compound had strong inhibitory activity against Vibrio alginolyticus, with a MIC of 0.5 μg / mL.

[0068] The above experimental results prove that the compounds involved in the present invention have strong inhibitory activity against multiple tumor cells and Vibrio alginolyticus, can be used as anti-tumor preparations or antibacterial agents, and are expected to be used in the preparation of related drugs in the form of any acceptable salt or with the addition of clinically acceptable excipients or carriers such as excipients and diluents.

Claims

1. A chaetoglobosin compound, characterized in that: The molecular structure of the compound is shown in Formula I, and its molecular formula is C 31 H 34 N2O3; Formula I.

2. A method for preparing the chaetoglobosin compound according to claim 1, characterized in that: 1) fermenting the activated mycelium of Chaetomium globosum in a solid culture medium, repeatedly extracting the fermentation product with ethyl acetate, combining the extracts and concentrating them to obtain a crude fermentation extract; 2) subjecting the fermentation crude extract in step 1) to vacuum silica gel column chromatography, eluting with a gradient of petroleum ether-ethyl acetate in a volume ratio of 20:1 to 1:1 and a gradient of dichloromethane-methanol in a volume ratio of 20:1 to 1:1; 3) purifying the fraction eluted in step 2) with a gradient elution of petroleum ether and ethyl acetate in a volume ratio of 1:1 by reverse phase column chromatography using methanol and water in a volume ratio of 10:90 to 100:0 as the eluent; 4) Collect the components eluted in the methanol-water volume ratio of 70:30 in step 3), separate them by gel column chromatography, and then separate and purify them by semi-preparative liquid phase 78% CH3CN / H2O2.5 mL / min to obtain the compound represented by formula I.

3. The method for preparing the chaetoglobosin compound according to claim 2, characterized in that: 1) The Chaetomium globosum Chaetomium globosum The culture was carried out on a potato sucrose agar PDA medium at 28°C for 7 days, and the mycelium was inoculated into a rice solid medium, and allowed to ferment at room temperature for 39 days. The fermentation product was extracted with petroleum ether to remove small polar metabolites, and then fully soaked and repeatedly extracted with ethyl acetate, and the extracts were combined and concentrated to obtain a crude extract; 2) The crude extract was subjected to reduced pressure silica gel column chromatography, and gradient elution was performed using a gradient elution system of petroleum ether-ethyl acetate in a volume ratio of 20:1 to 1:1 and a gradient elution system of dichloromethane-methanol in a volume ratio of 20:1 to 1:1; 3) collecting and concentrating the fractions eluted by the petroleum ether-ethyl acetate volume ratio of 1:1 in the above step 2), and gradient eluting the fractions by reverse phase silica gel column chromatography using a methanol-water elution system with a gradient volume ratio of 10:90 to 100:0; 4) Collecting the methanol-water volume ratio of 70:30 components in the above step 3), and then separating them by Sephadex LH-20 methanol gel column chromatography, and then purifying them by semi-preparative liquid phase separation to obtain the chaetoglobosin compound represented by formula I.

4. A use of the chaetoglobosin compound according to claim 1, characterized in that: The chaetoglobosin compounds of formula I are used in the preparation of drugs for treating human brain tumors, esophageal cancer, colon cancer, kidney cancer and bladder cancer.

5. A use of the chaetoglobosin compound according to claim 1, characterized in that: The chaetoglobosin compounds in formula I are used in the preparation of drugs for inhibiting Vibrio alginolyticus infection.

Citation Information

Patent Citations

  • Cytochalasin compounds and preparation method and application thereof

    CN101591288A

  • Chaetomium madrasense and application thereof

    CN110438013A

  • Cytochalasin compound, and preparation method and application thereof

    CN113861208A

  • Preparation method and application of chaetomium globosum compound

    CN115181057A

  • KR20210099921A